Validity of different dose reduction criteria for apixaban - 19/06/21
Doi : 10.1016/j.ahj.2021.03.004
Nathaniel M. Hawkins, MD a, ⁎ 
, Lee Er, MSc b, Roopinder K. Sandhu, MD, MPH c, d, Padma Kaul, PhD c, d, Finlay A. McAlister, MD, MSc d, e, Adeera Levin, MD b, f, Jason G. Andrade, MD a
, Lee Er, MSc b, Roopinder K. Sandhu, MD, MPH c, d, Padma Kaul, PhD c, d, Finlay A. McAlister, MD, MSc d, e, Adeera Levin, MD b, f, Jason G. Andrade, MD a a Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada
b BC Renal, Vancouver, British Columbia, Canada
c Division of Cardiology and Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
d Canadian Vigour Centre, University of Alberta, Edmonton, Alberta, Canada
e Division of General Internal Medicine, University of Alberta, Edmonton, Canada
f Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, Canada
⁎Reprint requests: Nathaniel M Hawkins, MD, Centre for Cardiovascular Innovation, University of British Columbia, 2775 Laurel Street, 9th Floor Room 9123, Vancouver, British Columbia, V5Z 1M9, CanadaCentre for Cardiovascular InnovationUniversity of British Columbia2775 Laurel Street, 9th Floor Room 9123VancouverBritish ColumbiaV5Z 1M9,Canada
Abstract |
Reduced-dose apixaban is recommended in patients fulfilling 2 of 3 criteria: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL. However, patient weight is often not available in electronic health data. We examined the validity of alternative definitions based on age and renal function alone using an observational dataset of patients with atrial fibrillation and chronic kidney disease which included weight measurements.
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2021
Elsevier Inc. Tutti i diritti riservati.
Vol 238
P. 12-15 - Agosto 2021 Ritorno al numero
Articolo precedente
- Individuals aged 1-64 years with documented congenital heart defects at healthcare encounters, five U.S. surveillance sites, 2011-2013
- M. Jill Glidewell, Sherry L. Farr, Wendy M. Book, Lorenzo Botto, Jennifer S. Li, Aida S. Soim, Karrie F. Downing, Tiffany Riehle-Colarusso, Alfred A D'Ottavio, Marcia L. Feldkamp, Amber D. Khanna, Cheryl L. Raskind-Hood, Kristin M. Sommerhalter, Tessa L Crume
- Neighborhood education status drives racial disparities in clinical outcomes in PPCM
- Kelly D. Getz, Jennifer Lewey, Vicky Tam, Olga Corazon Irizarry, Lisa D. Levine, Richard Aplenc, Zolt Arany
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?